Wire · opportunities
Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 September 2026 · Fusion42 review
Teva Pharmaceutical's experimental monoclonal antibody TEV-53408 has shown successful prevention of gluten-induced intestinal damage in a Phase 2a clinical trial for celiac disease, a condition with no current FDA-approved treatments. The drug demonstrated safety, symptom improvement, and significant biological efficacy, advancing towards further clinical development with potential blockbuster sales.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 2 Sep 2026 and 3 Sep 2026.
◆ ◆ The Wire takeaway
You can now position your biotech company around IL-15 targeted therapies with stronger evidence of clinical benefit in celiac disease. This opens a door to innovate beyond diet management towards approved treatments that address the biological cause.
◆ Coverage
3 sources · first reported 2 Sep 2026 · latest 3 Sep 2026
◆ Related on Wire
◆ Topics